Jove
Visualize
Contact Us

Related Concept Videos

Electroconvulsive Therapy01:30

Electroconvulsive Therapy

229
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
229

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The role of immunomodulators in severe mental disorders: future perspectives.

Current opinion in psychiatry·2024
Same author

Anhedonia is associated with a specific depression profile and poor antidepressant response.

The international journal of neuropsychopharmacology·2024
Same author

Hypomanic symptoms in major depressive disorder: Prognostic impact and treatment issues.

Journal of affective disorders·2024
Same author

Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial - CORRIGENDUM.

The British journal of psychiatry : the journal of mental science·2024
Same author

Projections of anxiety disorder prevalence during and beyond the COVID-19 pandemic in Germany using the illness-death model.

BJPsych open·2024
Same author

Epigenome-Wide DNA Methylation in Unipolar Depression: Predictive Biomarker of Antidepressant Treatment Response?

The international journal of neuropsychopharmacology·2024
Same journal

Cannabis use patterns and psychotic-like experiences: a cross-sectional study of heavy users, occasional users, and non-users.

Journal of psychiatric research·2026
Same journal

Psychiatric or psychological treatment of depression in older adults and subsequent risk of dementia: Health and Retirement Study2012-2020.

Journal of psychiatric research·2026
Same journal

Analysis of the association between outdoor artificial light exposure and depressive symptoms in patients with different subtypes of depression.

Journal of psychiatric research·2026
Same journal

Linking socioeconomic context to functional brain network abnormalities and clinical severity in children with Tourette syndrome.

Journal of psychiatric research·2026
Same journal

Development and validation of the 5-item intimate partner violence scale (IPVS-5): Psychometric properties in a large-scale Chinese study.

Journal of psychiatric research·2026
Same journal

Sleep health profiles of young adult college students: A latent profile analysis.

Journal of psychiatric research·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Sep 27, 2025

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.4K

Immunological changes following electroconvulsive therapy in multiple sclerosis.

Erhan Kavakbasi1, Franziska Rodner1, Lavanja Nimalavachchlan1

  • 1Department of Psychiatry, University Hospital Münster, University of Münster, Münster, Germany.

Journal of Psychiatric Research
|April 7, 2022
PubMed
Summary
This summary is machine-generated.

Electroconvulsive therapy (ECT) is safe for treating severe depression in multiple sclerosis (MS) patients. This study found ECT improved depressive symptoms without worsening MS or causing neurodegeneration, potentially increasing neuroprotective pathways.

Keywords:
Bipolar depressionECTElectroconvulsive therapyImmunologyInflammationMSMultiple sclerosisTreatment resistant depression

More Related Videos

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice
05:44

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice

Published on: October 13, 2023

1.6K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

3.9K

Related Experiment Videos

Last Updated: Sep 27, 2025

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.4K
Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice
05:44

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice

Published on: October 13, 2023

1.6K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

3.9K

Area of Science:

  • Neuroscience
  • Psychiatry
  • Immunology

Background:

  • Electroconvulsive therapy (ECT) is a recognized treatment for treatment-resistant depression (TRD).
  • Limited data exists on ECT's efficacy and safety in patients with multiple sclerosis (MS), particularly regarding neurological effects.
  • This case study investigates ECT in a patient with both TRD and MS.

Observation:

  • A middle-aged male patient with MS on dimethyl fumarate experienced severe bipolar depression.
  • The patient underwent 14 ECT sessions, with a switch from right-unilateral to bilateral stimulation.
  • Depression severity, neurodegeneration, and inflammation biomarkers were monitored before and after ECT.

Findings:

  • ECT was well-tolerated, with no neurological deterioration or new symptoms observed.
  • A partial response to ECT was noted, with a 35% improvement in depression scores (BDI-II and MADRS).
  • Biomarker analysis showed low levels of inflammation and neurodegeneration, with a notable increase in the CCL-2 pathway post-ECT.

Implications:

  • ECT appears safe and feasible for treating TRD in patients with MS.
  • The findings suggest ECT may not activate MS or cause neurodegeneration and could potentially offer neuroprotection.
  • Further research is warranted to explore ECT's neurobiological impact in MS patients with depression.